Orbimed Advisors LLC Passage Bio, Inc. Transaction History
Orbimed Advisors LLC
- $4.24 Billion
- Q3 2024
A detailed history of Orbimed Advisors LLC transactions in Passage Bio, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 9,822,876 shares of PASG stock, worth $6.38 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
9,822,876
Previous 10,124,576
2.98%
Holding current value
$6.38 Million
Previous $8 Million
14.03%
% of portfolio
0.16%
Previous 0.19%
Shares
5 transactions
Others Institutions Holding PASG
# of Institutions
47Shares Held
38.7MCall Options Held
7.7KPut Options Held
0-
Lynx1 Capital Management LP San Juan, PR8.43MShares$5.48 Million2.11% of portfolio
-
Vestal Point Capital, LP New York, NY6.1MShares$3.97 Million0.32% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY2.5MShares$1.62 Million1.8% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.46MShares$1.6 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.07MShares$1.35 Million0.0% of portfolio
About Passage BIO, Inc.
- Ticker PASG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,463,200
- Market Cap $35.4M
- Description
- Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...